Clinical Trials for Transitional Cell Carcinoma
Transitional cell carcinoma (TCC) is a malignant tumor arising from the transitional epithelium of the urinary tract in dogs and cats, most commonly affecting the bladder and urethra. It is particularly prevalent in certain dog breeds including Scottish Terriers and Beagles. University research programs are actively studying targeted therapies, immunotherapy, and new drug combinations through funded clinical trials that may significantly reduce or eliminate treatment costs.
11 active trials currently enrolling
Trials available at institutions in:
Understanding Transitional Cell Carcinoma in Pets
Transitional cell carcinoma (TCC) arises from the lining of the bladder and urinary tract and is the most common urinary tract cancer in dogs and cats. It can cause urinary symptoms and tends to be locally invasive.
Who it tends to affect
- Typical size: Affects both dogs and cats; in dogs, small-to-medium breeds are disproportionately represented
- Typical age: Most commonly diagnosed in older animals
Breeds it's seen in more often
Scottish Terriers, Beagles, Shetland Sheepdogs.
This is which breeds tend to develop transitional cell carcinoma — not a list of who can join a trial. See eligibility below.
Can my pet join — does breed matter?
Trials typically enroll based on tumor location, imaging, and prior treatment. Dogs and cats of all breeds meeting study criteria are generally eligible. The listed breeds have documented higher rates in dogs specifically.
Most trials are open to all breeds and set requirements by size, weight, age, and diagnosis instead. Our matching service checks your pet's specific details against each study's actual requirements.
Where Transitional Cell Carcinoma Trials Are Running
Active research locations are spread across the country. Current coverage by region:
States with active sites include: MO, WI, CO, KS, IN. We expand the search to nearby states when there's no local match.
What Transitional Cell Carcinoma Trials Typically Cost
Many trials cover part or all of treatment costs. Of the 11 trials we're currently tracking for transitional cell carcinoma:
The trials themselves are run by research institutions — we don't charge for them. Funding status changes as studies open and close, so we confirm current coverage when we match your pet.
What Transitional Cell Carcinoma Research Is Focused On
Current studies for transitional cell carcinoma are exploring approaches like:
- •Targeted drug therapy
- •Anti-inflammatory combinations
- •Immunotherapy
- •New chemotherapy protocols
How it works
Tell us about your pet
Share the diagnosis, your pet's age and size, and your location. It takes a few minutes — no account needed.
We research current trials
We check open studies against your pet's actual eligibility — diagnosis, stage, location, and prior treatment. Most matches come back in 2–3 days.
You get your matches
A personalized list of trials your pet may qualify for, with locations, funding status, and exactly how to enroll.
The trials themselves are free and run by research institutions. Our fee covers the research and eligibility matching — and if we don't find any matches for your pet, you don't pay.
Find trials for my pet with Transitional Cell Carcinoma now
Our matching service screens all 11 active Transitional Cell Carcinoma trials against your pet’s specific profile — age, breed, stage, and location.
$7 to see your matches · $23 only if trials are found
Check My Pet’s Eligibility Now →Find Trials for Your Pet
Our free matching service screens 147 active trials at 25 accredited veterinary universities. Submit once, get matched to every relevant trial.
Find Trials for Your Pet